Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes within the kidney. Inlyta works by blocking certain proteins called kinases that play a role in tumor growth and cancer progression. The recommended dose for Inlyta is 5mg taken orally two times a day. Clinical trial results showed a median progression-free survival of 6.7 months compared to 4.7 months with a standard treatment.
Biologics encompasses patient access, specialty pharmacy and care continuum services to provide a comprehensive solution that improves the patient experience and accelerates access to appropriate care. Recognized for its high-touch patient care model, Biologics’ oncology pharmacy services group includes a clinically relevant team with expertise in complex therapies to ensure patient adherence and compliance. As a result of its commitment to supporting cancer patients, Biologics has extensive prescriber relationships across the United States.
“It’s an honor to be selected as a Limited Distribution Network partner for Pfizer’s Inlyta,” said Stuart Frantz, Chief Executive Officer and President of Biologics, Inc. “We are committed to delivering the highest standard of care to patients and are excited to partner with Pfizer in providing another option to patients battling renal cell carcinoma.”